Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery
Surmodics, Inc. (NASDAQ:SRDX) has introduced the industry’s first suite of torqueable peripheral microcatheters through its Sublime Radial Access Platform. Dr. Ankur Lodha and Dr. Pradeep Nair were the first physicians to utilize the Sublime™ microcatheter, which is currently in limited market evaluation, with a full launch expected in FY 2024. This new line includes microcatheters designed for superior navigation of complex lesions in both transradial and transfemoral procedures. Notably, these microcatheters boast features like Pristyne™ hydrophilic coating and dual stainless steel locked-braid layers for enhanced torque control. The company’s commitment to expanding its endovascular devices portfolio aims to address unmet clinical needs and improve patient outcomes in peripheral artery disease.
- Launch of the world’s first suite of torqueable peripheral microcatheters under the Sublime brand.
- Successful initial use by leading interventional cardiologists indicating high performance in treating peripheral arterial disease.
- Potential to improve patient outcomes and enhance the adoption of radial access procedures.
- Plans for a full product launch in FY 2024, expanding the company’s market potential.
- Limited market evaluation period may hinder immediate revenue generation.
- Dependence on the upcoming full launch for significant market impact.
Sublime Radial Access Platform to include the industry’s first suite of torqueable peripheral microcatheters, designed for navigating tortuosity and crossing complex lesions and available for both transradial and transfemoral procedures
The Sublime microcatheter is in limited market evaluation. The full suite of Sublime microcatheters will be launched in FY 2024. The Sublime portfolio will include the industry’s first suite of 0.014”, 0.018”, and 0.035” high-performance peripheral microcatheters.
“For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients,” said
“The lack of long-length, high-performance catheters for peripheral procedures has slowed adoption of radial access for treatment of lower extremity artery disease,” added
Available in five lengths from 65 to 200 cm and compatible with 0.014”, 0.018”, and 0.035” guidewires, the Sublime microcatheters feature Surmodics’ best-in-class Pristyne™ hydrophilic coating for superb lubricity to optimize device trackability through vessel tortuosity. The device’s dual stainless steel, locked-braid layers work in unison to optimize torque control, push transmission, and deliverability to distal target lesions. The microcatheters are available in straight or angled tip configurations to access all types of peripheral vessels within their indicated size range. The Sublime 0.014” and 0.018” microcatheters can be telescoped through the 0.035” Sublime microcatheter to provide additional back up support when navigating extreme tortuosity or heavily stenosed lesions. This combination of optimized torque and stackability is designed to bring a new level of deliverability and crossing performance to the peripheral vascular space.
“This successful first use of our Sublime microcatheters is a major milestone, not only for
The new line of Surmodics’ Sublime microcatheters, along with Surmodics’ guide sheaths and 0.014” and 0.018” RX PTA dilation catheters, round out a complete line of Sublime Radial Access Platform products. These products represent Surmodics’ commitment to leading the radial revolution with its expanding portfolio of endovascular devices purpose-designed to facilitate the treatment of above- or below-the-knee peripheral lesions via a transradial approach.
About
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about the anticipated launch of the full suite of Sublime microcatheters and the company’s growth strategy, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the results from current LMEs, the availability of products for commercial launch, and the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10‑K for the fiscal year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005402/en/
Surmodics Investor Inquiries:
ir@surmodics.com
Surmodics Public Relations Inquiries
pr@surmodics.com
Source:
FAQ
What is Surmodics' latest product in the stock symbol SRDX?
When will the Sublime microcatheters be fully launched?
What medical procedure does the Sublime microcatheter aim to improve?
Who were the first physicians to use the Sublime microcatheter?